CSPC Deal History & Licensing Activity
CSPC is a large biotech headquartered in USA. Over the past three years, CSPC has been involved in 10 licensing and acquisition transactions, with a primary focus on Other (14 deals).
Deals (12mo)
1
Active Trials
0
Top Modality
Other
Focus Area
Mega Deals
CSPC Recent Deal Activity
Licensing, acquisition, and partnership transactions involving CSPC in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| Next-generation cardiometabolic therapies | AstraZeneca | Small Molecules | Unknown | option | Jul 18, 2026 |
| Obesity/chronic disease program | AstraZeneca | Other | Unknown | collaboration | Jul 12, 2026 |
| kidney drug discovery program | AstraZeneca | Other | Discovery | collaboration |
CSPC Pipeline Focus
Therapeutic areas and modalities where CSPC is most active based on deal history and clinical trial data.
CSPC Strategic Signals
Key indicators of CSPC's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
See How Your Asset Matches CSPC's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Mega Deals assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Metabolic Deal Benchmarks
Market sizing, deal terms, and competitive landscape for metabolic
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
About CSPC Licensing & Deal Activity
CSPC is a large biotech company based in USA that has been actively engaged in licensing transactions across the biopharma landscape. With 10 deals over the past three years, CSPC ranks among the most acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for CSPC include Mega Deals (11 deals and trials), Option Deals (2 deals and trials), Metabolic (2 deals and trials), and Codev Deals (2 deals and trials). In terms of modality, CSPC has shown particular interest in other, small molecules.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for CSPC and 850+ other biopharma companies. Use our Solidus to benchmark your asset against CSPC's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.